|
|||||
|
Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter |
Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Feb 23 | Sale | 24.76 | 11,983 | 296,650 | 17,994 | Feb 24 05:34 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Feb 18 | Sale | 25.17 | 2,306 | 58,042 | 9,496 | Feb 23 04:40 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jun 09 | Sale | 24.60 | 882 | 21,697 | 0 | Jun 11 04:36 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Apr 15 | Sale | 19.72 | 28,920 | 570,288 | 0 | Apr 16 04:35 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Feb 20 | Option Exercise | 0.00 | 10,095 | 0 | 27,131 | Feb 23 09:25 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Feb 21 | Option Exercise | 0.00 | 6,875 | 0 | 30,942 | Feb 23 09:25 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Feb 16 | Option Exercise | 0.00 | 3,375 | 0 | 18,208 | Feb 18 07:25 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jun 07 | Option Exercise | 0.00 | 1,250 | 0 | 15,201 | Jun 08 04:21 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Feb 21 | Option Exercise | 0.00 | 6,875 | 0 | 15,955 | Feb 24 04:13 PM |
ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Feb 16 | Option Exercise | 0.00 | 3,375 | 0 | 10,252 | Feb 18 04:10 PM |
ALKS | Hopkinson Craig C. | SVP, Med Dev/Med Affairs, CMO | Jun 07 | Option Exercise | 0.00 | 1,250 | 0 | 7,245 | Jun 10 05:13 PM |
ALKS | Hopkinson Craig C. | SVP, Med Dev/Med Affairs, CMO | Feb 16 | Option Exercise | 0.00 | 3,375 | 0 | 7,078 | Feb 19 07:03 PM |
ALKS | Hopkinson Craig C. | SVP, Med Dev/Med Affairs, CMO | Jun 07 | Option Exercise | 0.00 | 1,250 | 0 | 1,250 | Jun 08 05:31 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite